Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying antirheumatic drugs

P G Conaghan1, T Lehmann, P Brooks

  • 1Department of Medicine, University of New South Wales, St. Vincent's Hospital, Darlinghurst, Australia.

Current Opinion in Rheumatology
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous mark-release recapture to improve estimates of movement and survival of the African malaria mosquitoes.

bioRxiv : the preprint server for biology·2026
Same author

Correlation of brain injury biomarkers with brain dysfunction, brain injury, and outcomes in critically ill patients: a post hoc exploratory analysis.

Infection·2026
Same author

Accuracy of dual-energy computed tomography (CT), ultrasound, cone-beam CT, and spectral photon-counting CT for detecting calcium crystal deposition in the osteoarthritic hand: a cross-sectional diagnostic test study.

Scandinavian journal of rheumatology·2026
Same author

PROspectiVe imaging research DEsign and coNducT (PROVIDENT): Considerations for clinical trials and studies using imaging (Part I).

Radiography (London, England : 1995)·2026
Same author

PROspectiVe imaging research DEsign and coNducT (PROVIDENT): Considerations for clinical trials and studies using imaging (Part II).

Radiography (London, England : 1995)·2026
Same author

Combining Machine-Learning Assessment of Multiple MRI Pathologies and Clinical Phenotypes for Predicting Joint Replacement in Knee Osteoarthritis: Data From the Osteoarthritis Initiative.

Cartilage·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Early intervention with disease-modifying antirheumatic drugs (DMARDs) is supported by new evidence. Triple DMARD therapy showed benefits over individual agents, though drug toxicity remains a concern.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Published reports in the past year strengthen the rationale for early intervention with disease-modifying antirheumatic drugs (DMARDs).
  • Key DMARDs discussed include methotrexate, gold, sulfasalazine, and antimalarial agents.
  • The American College of Rheumatology released updated guidelines for rheumatoid arthritis management and drug toxicity monitoring.

Purpose of the Study:

  • To review recent advancements in disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis.
  • To highlight findings on DMARD mechanisms of action, focusing on cytokine interactions.
  • To assess the efficacy and safety profile of DMARDs, including potential toxic effects.

Main Methods:

  • Review of published literature from the past year concerning DMARDs.

Related Experiment Videos

  • Analysis of studies investigating the effects of DMARDs on cytokines and their receptors.
  • Examination of clinical trial data, including a significant trial on triple DMARD therapy.

    • Main Results:

    • Recent studies reinforce the importance of early intervention with DMARDs.
    • Research has elucidated the impact of DMARDs on cytokine pathways.
    • A key trial indicated superior efficacy of triple DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine) compared to monotherapy.
    • Adverse effects of DMARDs, particularly pulmonary toxicity associated with methotrexate, remain a critical consideration.

    Conclusions:

    • Evidence supports the early use of DMARDs in rheumatoid arthritis management.
    • Understanding DMARD mechanisms involving cytokines is advancing.
    • Triple DMARD therapy presents a promising treatment strategy, though careful monitoring for toxicity is essential.